Together, both companies will be able to discover, develop and market new macrocyclic molecules, by combining their knowledge through technology platforms dedicated to chemistry and biology.

Under the terms of the contract, and as mentioned by the Group, « Oncodesign will mainly be in charge of the phases of selection and chemical optimization of the selected compounds, until the drug candidate selection stage for the targets in oncology and possibly outside oncology. Bristol-Myers Squibb will be for its part in charge of pursuing the preclinical and clinical development of all the products that result from the collaboration, as well as their global marketing.

In addition to an initial payment of 3 million dollars, the terms of the partnership contract specify that Oncodesign is eligible for an amount up to 80 million dollars per target depending on the milestones achieved on research, development and regulatory aspects, on progressive royalties on the future sales and on additional payments depending on the trade performance of the products developed under this collaboration.

Having advised Oncodesign for many years, in fund raising, in the stock market listing, in acquisitions as well as in its social management and contractual arrangements with its partners, LAMY LEXEL Lawyers Partners assisted the company in implementing this partnership.

Aurélie DANTZIKIAN-FRACHON, partner in the Competition & Distribution department, assisted the management team in the negotiations and contributed to finalize a major strategic collaboration between Oncodesign and Bristol-Myers Squibb.